Combination therapy produces greater weight loss All treatment groups had improvements in fasting glucose, mean glucose, insulin sensitivity and insulin secretion at 24 weeks
Preclinical studies have shown that GIP may reduce body weight by reducing food intake and increasing energy consumption, and in combination with GLP-1 receptor agonists, may have a greater effect on patients' blood glucose and body weight
GLP-1 medications are not universally prohibited, but temporary deferrals apply because these agents affect glucose metabolism, cardiovascular function, and fluid statusfactors that influence plasma stability and recipient safety
2003 Jun-Aug;24(3-4):233-40
THE VITASTIR PROMISE Our B12 shots and vitamin injections are specially formulated in a FDA registered, PCAB sterile pharmacy
Taking a dose one day early is unlikely to cause serious problems because the medicine stays in your system for several days